Seaport Therapeutics (NASDAQ:SPTX) Stock Breaks Above 50-Day Moving Average – Time to Sell?

Shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $20.68 and traded as high as $21.75. Seaport Therapeutics shares last traded at $21.50, with a volume of 227,030 shares changing hands.

Seaport Therapeutics News Roundup

Here are the key news stories impacting Seaport Therapeutics this week:

• Positive Sentiment: Director Denice Torres bought 5,000 shares for about $99,300 at an average price of $19.86, a notable insider purchase that may signal confidence in the company. Article: Seaport Therapeutics Director Purchases Shares
• Positive Sentiment: JPMorgan raised its price target to $41 from $40 and maintained an Overweight rating. HC Wainwright also reiterated its Buy rating and $50 target, reflecting continued analyst optimism, though targets are not guarantees. Seaport Therapeutics analyst information
• Neutral Sentiment: HC Wainwright made mixed earnings-estimate revisions: it narrowed its projected FY2026 loss to $3.95 per share from $4.09 and improved its Q4 2026 and Q1 2027 estimates, but its Q3 and Q4 2027 estimates imply somewhat larger losses. The revisions are modest and do not change its Buy rating or $50 target.
• Positive Sentiment: Seaport’s latest reported quarterly loss of $0.49 per share was better than the $0.58 loss analysts expected, providing a recent earnings beat that may help cushion concerns about future losses.

Analyst Ratings Changes

Several brokerages have recently weighed in on SPTX. JPMorgan Chase & Co. upped their price objective on shares of Seaport Therapeutics from $40.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday. Canaccord Genuity Group assumed coverage on shares of Seaport Therapeutics in a report on Wednesday, October 14th. They set a “buy” rating and a $28.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Seaport Therapeutics in a report on Thursday, October 8th. Seaport Research Partners set a $28.00 price target on Seaport Therapeutics in a research report on Wednesday, October 14th. Finally, Raymond James Financial began coverage on shares of Seaport Therapeutics in a research note on Friday, September 25th. They issued a “strong-buy” rating and a $46.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.12.

Seaport Therapeutics Stock Up 5.4%

The company has a market cap of $1.15 billion and a P/E ratio of -1.77. The stock’s fifty day moving average price is $20.68.

Seaport Therapeutics (NASDAQ:SPTX) last announced its earnings results on Monday, November 2nd. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.09. On average, equities analysts anticipate that Seaport Therapeutics, Inc. will post -4.35 earnings per share for the current fiscal year.

Insider Activity at Seaport Therapeutics

In other news, Director Denice Torres bought 5,000 shares of the stock in a transaction dated Tuesday, November 3rd. The shares were acquired at an average price of $19.86 per share, with a total value of $99,300.00. Following the acquisition, the director owned 5,000 shares in the company, valued at $99,300. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Hedge Funds Weigh In On Seaport Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SPTX. HighTower Advisors LLC purchased a new position in Seaport Therapeutics in the second quarter worth about $362,000. Squarepoint Ops LLC acquired a new stake in shares of Seaport Therapeutics during the second quarter valued at $538,000. Alps Advisors Inc. boosted its stake in shares of Seaport Therapeutics by 30.5% in the third quarter. Alps Advisors Inc. now owns 70,921 shares of the company’s stock valued at $1,430,000 after purchasing an additional 16,593 shares during the period. State Street Corp bought a new stake in shares of Seaport Therapeutics during the second quarter valued at approximately $1,448,000. Finally, Alyeska Investment Group L.P. bought a new stake in Seaport Therapeutics in the second quarter worth $1,629,000.

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company uses its Glyph platform, a technology designed to create prodrugs that may improve the delivery, tolerability, and effectiveness of certain therapies, including treatments intended to reach the brain.

Seaport’s pipeline includes investigational therapies for neurological and neuropsychiatric conditions. Its programs have included GTX-102, an oral investigational medicine being developed for Angelman syndrome, a rare genetic neurodevelopmental disorder, as well as additional candidates aimed at addressing unmet needs in CNS care.

The company was established with support from PureTech Health and is headquartered in Boston, Massachusetts.